Sanofi ADR

Yahoo Finance • last month

Novavax Cut Its Outlook Despite Beating Third-Quarter Forecasts. Is It A Sell?

Things were looking up for Novavax stock after the FDA resolved a clinical hold. But the company trimmed its outlook. Is NVAX stock a sell? Continue reading View comments... Full story

Yahoo Finance • 2 months ago

Sanofi enters exclusive talks with CD&R for Opella sale

PARIS (Reuters) - Sanofi said on Monday it had entered exclusive negotiations for the sale of a 50% controlling stake in its consumer health business Opella to U.S. private equity firm Clayton Dubilier & Rice (CD&R). The French pharmceuti... Full story

Yahoo Finance • 2 months ago

Press Release: Sanofi and CD&R partner to fuel Opella’s ambitions in consumer healthcare

Sanofi - Aventis Groupe Sanofi and CD&R partner to fuel Opella’s ambitions in consumer healthcare Sanofi and CD&R enter exclusive negotiations to transfer a 50% controlling stake in Opella with Sanofi to remain a significant shareholder... Full story

Yahoo Finance • 2 months ago

Sanofi to sell 51% stake in Opella to CD&R, 1% to BPI

PARIS (Reuters) - France will take a stake in Sanofi's Opella through the Public Investment Bank (BPI), finance minister Antoine Armand said on Sunday, confirming an information from Le Figaro newspaper that U.S. private equity firm Clayto... Full story

Yahoo Finance • 2 months ago

Sanofi Set to Sign Consumer Health Deal With CD&R This Weekend

(Bloomberg) -- Sanofi is aiming to sign an agreement this weekend to sell control of its consumer health business to Clayton Dubilier & Rice, following a last-ditch attempt by a rival bidder to derail the deal, people with knowledge of the... Full story

Yahoo Finance • 2 months ago

PAI Partners to Raise Offer for Sanofi’s Consumer Unit

(Bloomberg) -- PAI Partners has submitted an improved offer for Sanofi’s consumer health business, according to people familiar with the matter, a potential twist to one of the biggest deals in Europe this year. Most Read from Bloomberg... Full story

Yahoo Finance • 3 months ago

Sanofi, GSK, CSL Tapped to Expand US Bird Flu Vaccine Supply

(Bloomberg) -- GSK Plc, Sanofi and CSL Ltd. secured $72 million from the US government to ramp up production of bird flu vaccines as a nationwide outbreak among livestock and poultry has led to several human infections that have raised con... Full story

Yahoo Finance • 3 months ago

Market Chatter: Sanofi Asks Bidders to Revise Offers for Consumer Health Unit

Market Chatter: Sanofi Asks Bidders to Revise Offers for Consumer Health Unit... Full story

Yahoo Finance • 3 months ago

Amgen's Rocatinlimab Has Commercial Potential Despite Competitive Landscape, Says Goldman Sachs

Amgen's Rocatinlimab Has Commercial Potential Despite Competitive Landscape, Says Goldman Sachs In an investor update on Tuesday, Amgen Inc (NASDAQ:AMGN) released data from Phase 3 trials of rocatinlimab and Uplizna (inebilizumab). HORIZ... Full story

Yahoo Finance • 3 months ago

Amgen's Rocatinlimab Data Beats Placebo In Atopic Dermatitis Trial, But Analyst Says Data Raises Concerns Amid Competitive Market

Amgen's Rocatinlimab Data Beats Placebo In Atopic Dermatitis Trial, But Analyst Says Data Raises Concerns Amid Competitive Market In an investor update on Tuesday, Amgen Inc (NASDAQ:AMGN) released data from Phase 3 trials of rocatinlimab... Full story

Yahoo Finance • 3 months ago

Sanofi's Tolebrutinib Delays Disability Progression In Patients With Multiple Sclerosis, Data Shows

Sanofi's Tolebrutinib Delays Disability Progression In Patients With Multiple Sclerosis, Data Shows Friday, Sanofi SA (NASDAQ:SNY) released data from the HERCULES phase 3 study of tolebrutinib for non-relapsing secondary progressive multi... Full story

Yahoo Finance • 4 months ago

Sanofi Still Bets On Multiple Sclerosis Med Tolebrutinib Despite The Investigational Drug Fell Short In 2 Of 3 Phase 3 Trials

Sanofi Still Bets On Multiple Sclerosis Med Tolebrutinib Despite The Investigational Drug Fell Short In 2 Of 3 Phase 3 Trials Sunday, Sanofi SA’s (NASDAQ:SNY) data from the HERCULES phase 3 study showed that tolebrutinib met the primary e... Full story

Yahoo Finance • 4 months ago

Top 25 Eco-Friendly Companies in 2024

In this article, we will look at the top 25 eco-friendly companies in 2024. If you want to skip our detailed analysis, you can go directly to the Top 5 Eco-friendly Companies in 2024. Environmental, Social, and Governance July 2024 broke... Full story

Yahoo Finance • 6 months ago

Europe Approves Sanofi/Regeneron's Dupixent for 'Smoker's Lungs' A Month After US FDA Asks For Data

Europe Approves Sanofi/Regeneron's Dupixent for 'Smoker's Lungs' A Month After US FDA Asks For Data On Wednesday, the European Medicines Agency (EMA) approved Dupixent (dupilumab) as an add-on maintenance treatment for adults with uncontr... Full story

Yahoo Finance • 6 months ago

Press Release: Availability of the Q2 2024 Aide-mémoire

Sanofi - Aventis Groupe Availability of the Q2 2024 Aide-mémoire Paris, France – June 25, 2024. Sanofi announced that its Q2 2024 Aide-mémoire is available on the "Investors" page of the company's website: https://www.sanofi.com/en/inve... Full story

Yahoo Finance • 6 months ago

Sanofi Seeks Initial Offers for Its $20 Billion Consumer Arm

(Bloomberg) -- Sanofi SA has called for initial bids for its $20 billion consumer health division, as the French pharmaceutical giant simultaneously moves forward with preparations for a possible listing of the business, according to peopl... Full story

Yahoo Finance • 6 months ago

Press Release: Sanofi and Biovac spearhead polio vaccine manufacturing capabilities in Africa

Sanofi - Aventis Groupe Sanofi and Biovac spearhead polio vaccine manufacturing capabilities in Africa Paris, June 20, 2024. Sanofi and Biovac, a Cape Town, South Africa-based biopharmaceutical company, announce today their local manufac... Full story

Yahoo Finance • 7 months ago

I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer

ROCKVILLE, Md., June 6, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for t... Full story

Yahoo Finance • 7 months ago

2 Incredible Growth Stocks to Buy Hand Over Fist Right Now

Despite some turbulence, growth stocks have been on a bull run since the 2008 financial crisis. Groundbreaking innovations in technology and healthcare have been the primary drivers behind this trend. Which growth stocks stand out as top... Full story

Yahoo Finance • 8 months ago

Sanofi SA's Dividend Analysis

Exploring the Sustainability and Growth of Sanofi SA's Dividends Sanofi SA (NASDAQ:SNY) recently announced a dividend of $2.04 per share, payable on 2024-06-06, with the ex-dividend date set for 2024-05-09. As investors look forward to th... Full story